JAK2 and hematologic disorder: ➢Is an inhibitor of several CDKs (CDK9: 3 nM, CDK5: 4 nM, CDK2: 5 nM, CDK3: 8 nM, CDK1: 9 nM, CDK7: 37 nM) together with JAK2 and FLT3. ➢Displays antiproliferative effects against tumor cell lines, induces cell-cycle arrest and apoptosis in leukemia cells, and prolongs survival in murine acute myeloid leukemia models.➢Inhibits transcription by inducing RNAP II Ser2 dephosphorylation and downregulates MCL-1 and XIAP, resulting into BAX activation and apoptosis.➢Is being evaluating in advanced hematologic malignancies and brain tumor.